Filatil (filgrastim biosimilar) / Probiomed - LARVOL DELTA

Development and validation of a cell-based methodology to evaluate filgrastim relative affinity to granulocyte colony-stimulating factor receptor. (PubMed, J Immunoassay Immunochem) - "After performing a validation exercise, the method proved to be accurate, specific, and linear within an affinity interval of 75 to 130%; precise with a confidence interval of 93.6 to 114.2% and a coefficient of variation of 12.6%. The validation exercise proved that the proposed cell-based method is a viable alternative to evaluate the biological activity of filgrastim via the affinity for its receptor and it is suitable to be included as part of its biological characterization exercises as well as in comparability exercises for products coming from distinct manufacturing processes."

Journal • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Oncology • CSF3R

Effectiveness of Innovator Pegfilgrastim (Neulastim®), Generic Pegfilgrastim (Linkix®) and Filgrastim for Engraftment after Auto-HSCT in an Outpatient Setting. (TCT-ASTCT-CIBMTR 2023) - P2 | "HL and NHL patients received a conditioning regimen with bendamustine (180mg/m 2 /day/2days) and melphalan (140mg/m 2 /1day). Time to neutrophil and platelet engraftment by treatment arm (Neulastim®, Linkix®, y filgrastim) Conclusion In patients with lymphoma and multiple myeloma receiving auto-HSCT, generic pegfilgrastim (Linkix®) produced a similar neutrophil and platelet engraftment time to patent pegfilgrastim (Neulastim®). The use of pegfilgrastim produces a faster time to neutrophil and platelet engraftment compared to filgrastim."

Clinical • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Multiple Myeloma • Musculoskeletal Pain • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pain • Transplantation

Efficacy of three filgrastim-intended copies for hematopoietic stem cell mobilization in healthy adult and pediatric donors in Mexico. (PubMed, J Clin Apher) - "In conclusion, three FICs available in Mexico were efficacious and without immediate severe adverse effects, resulting in significant cost savings. Evaluation of immunogenicity and establishment of a pharmacovigilance program with the use of FICs is warranted."

Clinical • Journal